- Posted Date: October 20, 2014
- Open Date (Earliest Submission Date): January 26, 2015
- Letter of Intent Due Date(s): January 15, 2015; October 14, 2015; April 14, 2016; August10, 2016; April 14, 2017, August 10, 2017, by 5:00 PM local time of applicant organization.
- Application Due Date(s): February 26, 2015; November 25, 2015; May 26, 2016; September 21, 2016; May 26, 2017; September 21, 2017, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
- AIDS Application Due Date(s); Not Applicable
- Scientific Merit Review: June/July 2015; March/April 2016; September/October 2016; January/February 2017; September/October 2017; January/February 2018
- Advisory Council Review: September 2015; May 2016; January 2017; May 2017; January 2018; May 2018
- Earliest Start Date: September 2015; July 2016; April 2017; July 2017; April 2018; July 2018
This Funding Opportunity Announcement (FOA) invites U01 cooperative agreement applications for Physical Science-Oncology Projects (PS-OP). The goal of the PS-OPs is to foster the convergence of physical sciences approaches and perspectives with cancer research to advance our understanding of cancer biology and oncology by forming small transdisciplinary teams of physical scientists and cancer biologists/physician scientists. Examples of physical scientists may include engineers, physicists, mathematicians, chemists, and computer scientists. The PS-OPs, individually and as a collaborative Network along with other PS-OPs and the Physical Sciences-Oncology Centers (PS-OC), will support transdisciplinary research that: (1) establishes a physical sciences perspective within the cancer research community; (2) facilitates team science and field convergence at the intersection of physical sciences and cancer research; and (3) collectively tests physical sciences-based experimental and theoretical concepts of cancer and promotes innovative solutions to address outstanding questions in cancer research.